Rankings
▼
Calendar
COLL Q3 2022 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena
COLL
Collegium Pharmaceutical, Inc.
$1B
Q3 2022 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$127M
+61.1% YoY
Gross Profit
$59M
46.3% margin
Operating Income
$20M
16.1% margin
Net Income
$457,000
0.4% margin
EPS (Diluted)
$0.01
QoQ Revenue Growth
+2.8%
Cash Flow
Operating Cash Flow
$43M
Free Cash Flow
$43M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$1.0B
Stockholders' Equity
$197M
Cash & Equivalents
$134M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$127M
$79M
+61.1%
Gross Profit
$59M
$46M
+27.6%
Operating Income
$20M
$14M
+44.7%
Net Income
$457,000
$8M
-94.3%
Revenue Segments
Xtampza ER
$39M
31%
Belbuca
$39M
31%
Nucynta IR
$27M
21%
Nucynta ER
$17M
13%
Symproic
$4M
3%
Other
$1M
1%
Elyxyb
$218,000
0%
← FY 2022
All Quarters
Q4 2022 →